RxDoctor Payments Data

Jose Cumba, MD

Ophthalmology · Bayamon, PRNPI 1508847450

Payments from drug & device makers

$1,192in general payments, 2019–2025

Across 21 payments — averaging $56.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Puerto Rico Inc$436
  • Novartis$178
  • NEW World Medical,inc.$157
  • Bausch & Lomb Americas Inc.$126
  • AbbVie$99
  • GSK$76
  • plus $121 from 3 others

What the payments were for

  • Food & beverage$1,17499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon Puerto Rico Inc4$436
Novartis4$178
NEW World Medical,inc.2$157
Bausch & Lomb Americas Inc.2$126
AbbVie(2 entities)5$99
GSK1$76
Alcon1$52
Sight Sciences, Inc.1$44
ANI Pharmaceuticals, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,192 in reported general payments places this provider in the 65th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,684
Medicare patients
93
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorometholone593$37,976
RestasisCyclosporine53$34,567
XiidraLifitegrast36$25,546
LumiganBimatoprost38$9,680
Latanoprost533$6,997
Cyclosporine32$6,230
Alphagan PBrimonidine Tartrate30$5,893
Prednisolone Acetate146$5,635
CombiganBrimonidine Tartrate/Timolol20$4,154
Tobramycin-DexamethasoneTobramycin/Dexamethasone95$4,023
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$3,650
Brimonidine Tartrate34$3,051
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat81$2,820
Dorzolamide-TimololDorzolamide/Timolol/Pf18$2,436
Ciprofloxacin Hcl93$1,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$99$54,293141 claims
Bausch & Lomb Americas Inc.Xiidra$126$25,54636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →